Zynerba Pharmaceuticals, Inc. ZYNE
We take great care to ensure that the data presented and summarized in this overview for Zynerba Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ZYNE
View allLatest Institutional Activity in ZYNE
Top Purchases
Top Sells
About ZYNE
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Insider Transactions at ZYNE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 10
2023
|
Kenneth T Jones |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
115,520
-73.69%
|
-
|
|
Oct 10
2023
|
Kenneth T Jones |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+28.57%
|
-
|
|
Oct 10
2023
|
James E Fickenscher Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
548,087
-66.28%
|
-
|
|
Oct 10
2023
|
James E Fickenscher Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
170,000
+28.57%
|
-
|
|
Oct 10
2023
|
Pamela Stephenson |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
75,778
-68.44%
|
-
|
|
Oct 10
2023
|
Brian Rosenberger VP, Commercial & Business Dev. |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
369,559
-63.94%
|
-
|
|
Oct 10
2023
|
Brian Rosenberger VP, Commercial & Business Dev. |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+28.57%
|
-
|
|
Oct 10
2023
|
William J Federici |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
75,778
-68.44%
|
-
|
|
Oct 10
2023
|
Terri B Sebree President |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
766,241
-78.62%
|
-
|
|
Oct 10
2023
|
Terri B Sebree President |
BUY
Grant, award, or other acquisition
|
Direct |
170,000
+28.57%
|
-
|
|
Oct 10
2023
|
Albert P Parker Chief Legal Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
312,018
-57.42%
|
-
|
|
Oct 10
2023
|
Albert P Parker Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+23.39%
|
-
|
|
Oct 10
2023
|
Warren D Cooper |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
75,778
-68.44%
|
-
|
|
Oct 10
2023
|
Kenneth I Moch |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
75,778
-68.44%
|
-
|
|
Oct 10
2023
|
John P. Butler |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
80,765
-70.39%
|
-
|
|
Oct 10
2023
|
Daniel L Kisner |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
75,778
-68.44%
|
-
|
|
Oct 10
2023
|
Armando Anido Chairman & Chief Exec. Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
39,892
-100.0%
|
-
|
|
Oct 10
2023
|
Armando Anido Chairman & Chief Exec. Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
1,176,722
-80.25%
|
-
|
|
Oct 10
2023
|
Armando Anido Chairman & Chief Exec. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,000
+28.24%
|
-
|
|
Sep 13
2023
|
Armando Anido Chairman & Chief Exec. Officer |
SELL
Open market or private sale
|
Direct |
17,830
-1.87%
|
$17,830
$1.33 P/Share
|